1. Phase I dose-escalation study of ZK 304709, an oral multitarget tumor growth inhibitor (MTGI), administered for 14 days of a 28-day cycle;Ahmed;J. Clin. Oncol.,2006
2. Cdc2-cyclin E complexes regulate the G1/S phase transition;Aleem;Nat. Cell Biol.,2005
3. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes;Andrews;Org. Biomol. Chem.,2004
4. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles;Arienti;J. Med. Chem.,2005
5. In vivo activity of BI 2536, a potent and selective inhibitor of the mitotic kinase Plk1, in a range of human cancer xenograft models;Baum;Proc. AACR-NCI-EORTC Conf. Molecular Targets and Cancer Therapeutics,2005